Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma represents the first book of its kind to be dedicated solely to UTUC. Its aim is to improve understanding and eventually care of a disease that is greatly understudied and underappreciated, yet commonly dealt with by many
- PDF / 7,284,118 Bytes
- 206 Pages / 439.43 x 683.15 pts Page_size
- 6 Downloads / 201 Views
Upper Tract Urothelial Carcinoma
123
Upper Tract Urothelial Carcinoma
Shahrokh F. Shariat • Evanguelos Xylinas Editors
Upper Tract Urothelial Carcinoma
Editors Shahrokh F. Shariat Department of Urology and Comprehensive Cancer Center Medical University of Vienna Vienna, Austria
Evanguelos Xylinas Department of Urology Paris Descartes University Paris, France
ISBN 978-1-4939-1500-2 ISBN 978-1-4939-1501-9 (eBook) DOI 10.1007/978-1-4939-1501-9 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2014948335 © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
In 2014, urothelial carcinoma of the bladder (UCB) is the fifth most common malignancy and the ninth most common cause of cancer death in the United States [1]. Conversely, upper tract urothelial carcinoma (UTUC) accounts for only 5–10% of all urothelial carcinomas. Largely due to the relative preponderance of UCB, much of the clinical decision-making surrounding UTUC is extrapolated from evidence that is based on UCB patients [2]. In fact, a recent review found 238 randomized controlled trials in bladder cancer [3], while a systematic search of the best evidence for the management of UTUC yielded only three such trials whi
Data Loading...
